The title compound, spiro[1-bromo(S)-4-(R)-hydroxy-5-oxa-6-oxo-bicyclo[3.1.0]- hxane-2,2?-(3?-diethyl-α-(S)-4??-Cl-benzyloxyphosphonyl-4?-(1R,2S,5R)-menthyloxybutyrolact- one)] has been synthesized via the tandem a...The title compound, spiro[1-bromo(S)-4-(R)-hydroxy-5-oxa-6-oxo-bicyclo[3.1.0]- hxane-2,2?-(3?-diethyl-α-(S)-4??-Cl-benzyloxyphosphonyl-4?-(1R,2S,5R)-menthyloxybutyrolact- one)] has been synthesized via the tandem asymmetric reaction and it crystallizes in a mono- clinic system, space group P21 with a = 11.067(3), b = 12.484(2), c = 12.356(2) ?, β = 101.95°, C29H39BrClO10P, Mr = 693.93, V = 1670.2(6) ?3, Z = 2, Dc= 1.380 g/cm3, λ(MoKα) = 0.071073 nm, μ = 1.410 mm-1, F(000) = 720, the final R = 0.0570 and wR = 0.0758 for 6190 observed reflections with I > 2σ(I). The structure is characterized by the special combination of biologic phosphonyl group and one cyclopropane as well as two butyrolactones. The intermolecular hydrogen bond between O(3)–H(3A)…O(10) in the crystal lattice has been observed.展开更多
基金Supported by the National Natural Science Foundation of China (No. 29672004)
文摘The title compound, spiro[1-bromo(S)-4-(R)-hydroxy-5-oxa-6-oxo-bicyclo[3.1.0]- hxane-2,2?-(3?-diethyl-α-(S)-4??-Cl-benzyloxyphosphonyl-4?-(1R,2S,5R)-menthyloxybutyrolact- one)] has been synthesized via the tandem asymmetric reaction and it crystallizes in a mono- clinic system, space group P21 with a = 11.067(3), b = 12.484(2), c = 12.356(2) ?, β = 101.95°, C29H39BrClO10P, Mr = 693.93, V = 1670.2(6) ?3, Z = 2, Dc= 1.380 g/cm3, λ(MoKα) = 0.071073 nm, μ = 1.410 mm-1, F(000) = 720, the final R = 0.0570 and wR = 0.0758 for 6190 observed reflections with I > 2σ(I). The structure is characterized by the special combination of biologic phosphonyl group and one cyclopropane as well as two butyrolactones. The intermolecular hydrogen bond between O(3)–H(3A)…O(10) in the crystal lattice has been observed.
